Treatment of Cardiac Hemochromatosis
DOI:
https://doi.org/10.17140/HROJ-2-e002Abstract
Treatment of iron-overload states is important to prevent or reverse cardiac dysfunction. Removal of excess iron from the tissues in these patients reduces generation of free radicals, decreasing organ damage. Removal of excess iron stores includes therapeutic phlebotomy and iron-chelating agents.
References
Rivers J, Garrahy P, Robinson W, et al. Reversible cardiac dysfunction in hemochromatosis. Am Heart J. 1987; 113: 216-217.
Easley RM, Jr, Screiner BF, Jr, Yu PN. Reversible cardiomyopathy associated with hemochromatosis. N Engl J Med. 1972; 287: 866-867. doi: 10.1056/NEJM197210262871708
Niederau C, Fischer R, Sonnenberg A, et al. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med. 1985; 313: 1256-1262. doi: 10.1056/NEJM198511143132004
Rahko PS, Salerni R, Uretsky BF. Successful reversal by chelation therapy of congestive cardiomyopathy due to iron overload. J Am Coll Cardiol. 1986; 8: 436-440. doi: 10.1016/S0735-1097(86)80063-8
Barton JC, McDonnell SM, Adams PC, et al. Management of hemochromatosis. Ann Intern Med. 1998; 129: 932-939. doi: 10.7326/0003-4819-129-11_Part_2-199812011-00003
Jomova K, Valko M. Importance of iron chelation in free radical-induced oxidative stress and human disease. Curr Pharm Des. 2011; 17: 3460-3473. doi: 10.2174/138161211798072463
Crosby WH. Hemochromatosis: treatment to alleviate injury. Arch Intern Med. 1986; 146: 1910-1911. doi: 10.1001/ archinte.1986.00360220054009
Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guidelines for the management of heart failure: executive summary. A report of the American College of Cardiology Foundation/American heart association task force on practice guidelines. Developed in collaboration with the American College of Chest Physicians, Heart Rhythm Society, and International Society for Heart and Lung Transplantation. Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation. J Am Coll Cardiol. 2013; 62: 1495-1539. doi: 10.1016/j.jacc.2013.05.020
Adams PC, Barton JC. How i treat hemochromatosis. Blood. 2010; 116: 317-325. doi: 10.1182/blood-2010-01-261875
Pietrangelo A. Non-HFE hemachromatosis. Hepatology. 2004; 39: 21-29.
Bacon BR, Adams PC, Kowdley KV, et al. Diagnosis and management of hemochromatosis: 2011 practice guidelines by the American Association for the Study of Liver Diseases. Hepatology. 2011; 54: 328-343. doi: 10.1002/hep.24330
Adams PC, Kertesz AE, Valberg LS. Rate of iron reaccumulation following iron depletion in hereditary hemochromatosis. Im-plications for venesection therapy. J Clin Gastroenterol. 1993; 16: 207-210.
Shizukuda Y, Bolan CD, Tripodi DJ, et al. Significance of left atrial contractile function in asumptomatic subjects with hereditary hemochromatosis. Am J Cardiol. 2006; 98: 954-959. doi: 10.1016/j.amjcard.2006.04.040
Dabestani A, Child JS, Henze E, et al. Primary hemochromatosis: anatomic and physiologic characteristics of the cardiac ven-tricles and their response to phlebotomy. Am J Cardiol. 1984; 54: 153-159. doi: 10.1016/0002-9149(84)90321-7
Cecchetti G, Binda A, Piperno A, et al. Cardiac alterations in 36 consecutive patients with idiopathic haemochromatosis: poly-graphic and echocardiographic evaluation. Eur Heart J. 1991; 12: 224-230.
Aronow WS, Meister L, Kent JR. Atrioventricular block in familial hemochromatosis treated by permanent synchronous pace-maker. Arch Intern Med. 1969; 123: 433-435. doi: 10.1001/archinte.1969.00300140079018
Fabio G, Minonzio F, Delbini P, et al. Reversal of cardiac complications by deferiprone and deferoxamine combination therapy in a patient affected by a severe type of juvenile hemochromatosis (JH). Blood. 2007; 109: 362-364. doi: 10.1182/blood-2006-04-016949
Kontoghiorghes GL, Eracleous E, Economides C, et al. Advances in iron overload therapies: prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, LINA11 and their combinations. Curr Med Chem. 2005; 12: 2663-2681. doi: 10.2174/092986705774463003
Glickstein H, El RB, Link G, et al. Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences. Blood. 2006; 108: 3195-3203. doi: 10.1182/blood-2006-05-020867
Kontoghiorghes GL, Kolnagou A, Peng CT, et al. Safety issues of iron chelation therapy in patients with normal range iron stores including thalassemia, neurodegenerative, renal and infectious diseases. Expert Opin Drug Saf. 2010; 9: 201-206. doi: 10.1517/14740330903535845
Rombout-Sestrienkova E, De Jonge N, Martinakova K, et al. End-stage cardiomyopathy because of hereditary hemochromatoss successfully treated with erythrocytapheresis in combination with left ventricular assist device support. Circ Heart Fail. 2014; 7: 541-543. doi: 10.1161/CIRCHEARTFAILURE.114.001198
Caines AE, Kpodonu J, Massad MG, et al. Cardiac transplantation in patients with iron overload cardiomyopathy. J Heart Lung Transplant. 2005; 24: 486-488. doi: 10.1016/j.healun.2004.02.009
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Heart Research (HROJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.